Article Type
Changed
Fri, 01/04/2019 - 11:08
Display Headline
Afatinib in metastatic NSCLC with mutations

In July 2013, afatinib was approved by the US Food and Drug Administration for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Quiagen’s therascreen EGFR RGQ PCR Kit for detection of EGFR exon 19 deletions (del19) and exon 21 (L858R) substitution mutations was concurrently approved. Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has shown broad-spectrum activity against tumor cells with EGFR mutations.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Author and Disclosure Information

 

 

Issue
The Journal of Community and Supportive Oncology - 12(1)
Publications
Topics
Page Number
4-5
Legacy Keywords
NSCLC, non-small-cell lung cancer, afatinib, exon 19, therascreen, exon 21, L858R
Sections
Author and Disclosure Information

 

 

Author and Disclosure Information

 

 

Article PDF
Article PDF

In July 2013, afatinib was approved by the US Food and Drug Administration for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Quiagen’s therascreen EGFR RGQ PCR Kit for detection of EGFR exon 19 deletions (del19) and exon 21 (L858R) substitution mutations was concurrently approved. Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has shown broad-spectrum activity against tumor cells with EGFR mutations.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

In July 2013, afatinib was approved by the US Food and Drug Administration for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Quiagen’s therascreen EGFR RGQ PCR Kit for detection of EGFR exon 19 deletions (del19) and exon 21 (L858R) substitution mutations was concurrently approved. Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has shown broad-spectrum activity against tumor cells with EGFR mutations.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 12(1)
Issue
The Journal of Community and Supportive Oncology - 12(1)
Page Number
4-5
Page Number
4-5
Publications
Publications
Topics
Article Type
Display Headline
Afatinib in metastatic NSCLC with mutations
Display Headline
Afatinib in metastatic NSCLC with mutations
Legacy Keywords
NSCLC, non-small-cell lung cancer, afatinib, exon 19, therascreen, exon 21, L858R
Legacy Keywords
NSCLC, non-small-cell lung cancer, afatinib, exon 19, therascreen, exon 21, L858R
Sections
Citation Override
JCSO 2014;12:4-5
Disallow All Ads
Alternative CME
Article PDF Media